Welcome to our dedicated page for Quoin Pharmaceuticals news (Ticker: QNRX), a resource for investors and traders seeking the latest updates and insights on Quoin Pharmaceuticals stock.
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) is a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, with a primary emphasis on severe genetic skin disorders and related conditions. The QNRX news feed on Stock Titan aggregates company press releases and market-moving updates that shed light on the progress of its clinical pipeline, regulatory interactions and financing activities.
Investors following QNRX news can see detailed updates on the development of the company’s lead asset, QRX003, a topical lotion in late-stage pivotal trials for Netherton Syndrome. Quoin regularly reports clinical data from investigator-led pediatric studies and pivotal programs, describing changes in skin condition, pruritus, sleep disturbance and use of concomitant medications in Netherton Syndrome patients. News items also cover initial positive data in Peeling Skin Syndrome and the potential versatility of QRX003 across multiple rare skin diseases.
Regulatory and designation milestones are another key component of Quoin’s news flow. The company has announced Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency for QRX003 in Netherton Syndrome, as well as Rare Pediatric Disease Designation in the United States. These updates provide context on potential market exclusivity and incentives that may affect the long-term outlook for the program.
Quoin’s news also highlights broader corporate developments, including private placement financings with healthcare-focused institutional investors, adoption of equity incentive plans, leadership changes such as the appointment of a new chief financial officer and shareholder meeting outcomes. In addition, the company issues regular communications about its NETHERTON NOW awareness campaign, releasing video episodes that feature patients, advocates and experts discussing the burden of Netherton Syndrome. For readers tracking QNRX, this news stream offers an ongoing view into clinical progress, regulatory events, capital formation and patient advocacy efforts related to Quoin’s rare disease focus.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released a new episode of its NETHERTON NOW video series featuring Professor Jemima Mellerio, a leading expert in genetic skin diseases. The video highlights the severe challenges of Netherton Syndrome, particularly in infants and children.
The release follows Quoin's recent achievement of Rare Pediatric Disease Designation from the FDA for its lead product candidate QRX003, which complements its existing Orphan Drug status from the EMA. Professor Mellerio emphasizes that Netherton Syndrome is a serious genetic condition with associated mortality, especially in young patients, requiring intensive daily treatment.
Quoin Pharmaceuticals (NASDAQ: QNRX) has received Rare Pediatric Disease (RPD) Designation from the FDA for its lead asset QRX003, targeting Netherton Syndrome. This follows the Orphan Drug Designation granted by the European Medicines Agency in May 2025.
The RPD designation could make Quoin eligible for a Priority Review Voucher upon potential New Drug Application approval. The company reports encouraging efficacy data and safety profile from ongoing pivotal clinical studies for QRX003, which aims to be the first treatment for this severe genetic disease primarily affecting children under 18.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported positive initial clinical data from its ongoing Investigator Pediatric Peeling Skin Syndrome study for QRX003. After 12 weeks of treatment, the study showed significant improvements across multiple endpoints:
- Modified Ichthyosis Area Severity Index (M-IASI) improved from 36 to 12 - Investigator's Global Assessment (IGA) improved from severe (4) to mild (2) - Children's Dermatology Life Quality Index (CDQLI) improved from 19 to 11
The treatment was well-tolerated with no adverse events reported. Based on these positive results, the patient will continue treatment with QRX003, with another assessment scheduled after 24 weeks. This study may be the first formal clinical trial for Peeling Skin Syndrome, a rare genetic disease with no currently approved treatments.
The company demonstrated compelling clinical data showing almost complete skin healing and reduction/elimination of pruritus in both adult and pediatric patients. Notably, pediatric patients were able to discontinue previously required medications. The studies confirmed QRX003's mechanism of action as a broad-spectrum serine protease inhibitor.
Financial highlights show a cash position of $11.6 million as of March 31, 2025, expected to fund operations into Q1 2026. The company reported a net loss of $3.8 million for Q1 2025, compared to $2.3 million in Q1 2024.
Quoin expanded its patent portfolio and launched NETHERTON NOW, a community awareness initiative. The company is preparing for additional international clinical sites and a new FDA-cleared study at Northwestern University evaluating whole-body QRX003 application in 8-12 patients.
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical-stage specialty pharmaceutical company specializing in rare and orphan diseases, has scheduled the release of its Q1 2025 financial results for Tuesday, May 13, 2025, before market opening. The company will provide a comprehensive update including the quarter's key achievements, recent accomplishments, and financial performance for the period ending March 31, 2025.
Quoin Pharmaceuticals (NASDAQ: QNRX), a late clinical stage specialty pharmaceutical company, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company, which focuses on developing treatments for rare and orphan diseases, received official confirmation from Nasdaq's Listing Qualifications Department.
The achievement was marked by the company's ordinary shares maintaining a closing bid price of $1.00 or higher for 13 consecutive business days, meeting the criteria under Nasdaq Listing Rule 5550(a)(2). With this requirement satisfied, Nasdaq has formally closed the matter, ensuring Quoin's continued listing on the exchange.
Quoin Pharmaceuticals (NASDAQ: QNRX) has released the second episode of its 'Living with Netherton' video series, featuring 79-year-old Norma Coles, one of the earliest patients evaluated for Netherton Syndrome. The episode is part of the company's NETHERTON NOW awareness campaign.
Norma's remarkable story spans nearly eight decades, having been initially examined by Dr. Edward Netherton at the Cleveland Clinic in the late 1940s. Despite experiencing symptoms like fragile skin, recurring rashes, and 'bamboo hair,' she wasn't officially diagnosed until her mid-50s.
The company's lead product candidate, QRX003, is currently undergoing four clinical trials for Netherton Syndrome treatment. Initial data shows promising results, including improvements in skin healing, reduction in inflammation and pruritus, and enhanced quality of life. Quoin aims to develop the first FDA-approved treatment for this rare genetic disorder, as currently no approved treatments exist.
Quoin Pharmaceuticals (NASDAQ: QNRX) has reported additional positive clinical data from its ongoing pediatric Netherton Syndrome (NS) study of QRX003. After 6 weeks of whole-body treatment, the first patient's skin remains almost completely healed, demonstrating treatment durability.
Key outcomes include:
- Elimination of previously required medications (antibiotics, antivirals, antihistamines, glucocorticoids)
- Almost complete elimination of pruritus (itching)
- Zero nightly sleep disturbances without sedating medication
- No adverse events reported after 6 weeks
Based on these positive results, Quoin has received approval to begin whole-body QRX003 treatment on a second pediatric NS patient, with testing expected to commence within weeks.